vicriviroc
Sign in to saveAlso known as SCH 417690, SCH-417690, SCH-D690, SCH-DS
Vicriviroc, previously named SCH 417690 and SCH-D, is a pyrimidine CCR5 entry inhibitor of HIV-1. It was developed by the pharmaceutical company Schering-Plough. Merck decided to not pursue regulatory approval for use in treatment-experienced patients because the drug did not meet primary efficacy endpoints in late stage trials. Clinical trials continue in patients previously untreated for HIV.
~10 min read
Encyclopedic overview
10 sectionsContents
- HIV-1 background
- HIV-1 entry
- Coreceptors and tropism
- CCR5-Δ32
- SCH-C and vicriviroc
- Method of action
- Clinical trials
- Concerns surrounding CCR5 antagonists
- See also
- References
{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 470630044 | ImageFile = Vicriviroc structure.svg | ImageClass = skin-invert-image | ImageSize = 270px | IUPACName = 5-({4-[(3S)-4-{2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl}-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine | OtherNames = |Section1 = |Section2= |Section3= }} Vicriviroc, previously named SCH 417690 and SCH-D, is a pyrimidine CCR5 entry inhibitor of HIV-1. It was developed by the pharmaceutical company Schering-Plough. Merck decided to not pursue regulatory approval for use in treatment-experienced patients because the drug did not meet primary efficacy endpoints in late stage trials. Clinical trials continue in patients previously untreated for HIV.
==HIV-1 background==
Excerpted from Wikipedia’s “vicriviroc” article, available under the CC BY-SA 4.0 licence.